← Back to Calendar

Cytokinetics Q1 2026 Earnings

Cytokinetics · $CYTK
Standard Review Earnings
Catalyst Date
May 6, 2026
Time Remaining
23 days
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$65.75 +70.10%
+$27.10 today
Day: $64.58 – $67.90
Market Cap
N/A
Shares out: 123.16M
Float: 122.30M
52-Week Range
$29.31
$70.98
Current price is at 87% of 52-week range
Avg Volume
1.87M
Beta
0.48
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $CYTK catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + MYQORZO launch metrics + ACACIA-HCM update

Key Notes

Q1 2026 earnings expected May 6, 2026. First full quarter of MYQORZO commercial launch. Key data: market share vs BMS Camzyos, patient uptake, reimbursement access. ACACIA-HCM (non-obstructive HCM) readout expected Q2 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar